Nanjing King-friend Biochemical Pharmaceutical Co Ltd (SHG:603707) — Market Cap & Net Worth
Market Cap & Net Worth: Nanjing King-friend Biochemical Pharmaceutical Co Ltd (603707)
Nanjing King-friend Biochemical Pharmaceutical Co Ltd (SHG:603707) has a market capitalization of $1.69 Billion (CN¥11.54 Billion) as of June 26, 2026. Listed on the SHG stock exchange, this China-based company holds position #6864 globally and #1531 in its home market, demonstrating a -2.06% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Nanjing King-friend Biochemical Pharmaceutical Co Ltd's stock price CN¥7.14 by its total outstanding shares 1615651020 (1.62 Billion). Review how much debt does Nanjing King-friend Biochemical Pharmace carry to assess the company's total debt and financial obligations.
Nanjing King-friend Biochemical Pharmaceutical Co Ltd Market Cap History: 2017 to 2026
Nanjing King-friend Biochemical Pharmaceutical Co Ltd's market capitalization history from 2017 to 2026. Data shows growth from $1.73 Billion to $1.69 Billion (11.53% CAGR).
Nanjing King-friend Biochemical Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Nanjing King-friend Biochemical Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.53x
Nanjing King-friend Biochemical Pharmaceutical Co Ltd's market cap is 0.53 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.67x
Nanjing King-friend Biochemical Pharmaceutical Co Ltd's market cap is 3.67 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $1.73 Billion | $1.11 Billion | $314.22 Million | 1.56x | 5.51x |
| 2018 | $1.50 Billion | $1.70 Billion | $424.55 Million | 0.88x | 3.54x |
| 2019 | $4.35 Billion | $2.47 Billion | $604.96 Million | 1.76x | 7.18x |
| 2020 | $4.81 Billion | $2.91 Billion | $806.12 Million | 1.65x | 5.97x |
| 2021 | $7.52 Billion | $3.69 Billion | $1.06 Billion | 2.04x | 7.10x |
| 2022 | $4.23 Billion | $3.71 Billion | $1.09 Billion | 1.14x | 3.88x |
| 2023 | $3.55 Billion | $3.93 Billion | -$189.45 Million | 0.90x | N/A |
| 2024 | $3.14 Billion | $3.92 Billion | $826.14 Million | 0.80x | 3.80x |
| 2025 | $2.13 Billion | $3.99 Billion | $581.54 Million | 0.53x | 3.67x |
Competitor Companies of 603707 by Market Capitalization
Companies near Nanjing King-friend Biochemical Pharmaceutical Co Ltd in the global market cap rankings as of June 26, 2026.
Key companies related to Nanjing King-friend Biochemical Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #509 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #554 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #574 globally with a market cap of $46.71 Billion USD ( CN¥319.21 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #631 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #509 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #554 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $44.23 |
| #574 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $46.71 Billion | CN¥50.04 |
| #631 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.70 |
Nanjing King-friend Biochemical Pharmaceutical Co Ltd Historical Marketcap From 2017 to 2026
Between 2017 and today, Nanjing King-friend Biochemical Pharmaceutical Co Ltd's market cap moved from $1.73 Billion to $ 1.69 Billion, with a yearly change of 11.53%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.69 Billion | -20.93% |
| 2025 | CN¥2.13 Billion | -31.95% |
| 2024 | CN¥3.14 Billion | -11.53% |
| 2023 | CN¥3.55 Billion | -16.14% |
| 2022 | CN¥4.23 Billion | -43.78% |
| 2021 | CN¥7.52 Billion | +56.22% |
| 2020 | CN¥4.81 Billion | +10.80% |
| 2019 | CN¥4.35 Billion | +188.88% |
| 2018 | CN¥1.50 Billion | -13.08% |
| 2017 | CN¥1.73 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 26th, 2026 the market cap of Nanjing King-friend Biochemical Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.69 Billion USD |
| MoneyControl | $1.69 Billion USD |
| MarketWatch | $1.69 Billion USD |
| marketcap.company | $1.69 Billion USD |
| Reuters | $1.69 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Nanjing King-friend Biochemical Pharmaceutical Co Ltd
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of drugs and APIs in China. It also provides heparin sodium, enoxaparin sodium, dalteparin sodium, nadroparin calcium, atracurium besylate, cisatracurium, calcium folinate, doxorubicin, milrinone, bleomycin, carboplatin, cytarabine, topotecan hydrochloride, phenylephrine hydrochlo… Read more